Wall Street brokerages forecast that Atara Biotherapeutics, Inc. (NASDAQ:ATRA) will announce earnings per share (EPS) of ($1.15) for the current quarter, Zacks reports. Zero analysts have made estimates for Atara Biotherapeutics’ earnings. The lowest EPS estimate is ($1.23) and the highest is ($1.06). Atara Biotherapeutics reported earnings of ($0.63) per share during the same quarter last year, which would indicate a negative year over year growth rate of 82.5%. The firm is expected to announce its next earnings results on Thursday, March 8th.

According to Zacks, analysts expect that Atara Biotherapeutics will report full-year earnings of ($4.00) per share for the current year, with EPS estimates ranging from ($4.08) to ($3.91). For the next fiscal year, analysts anticipate that the company will post earnings of ($4.62) per share, with EPS estimates ranging from ($4.97) to ($4.27). Zacks Investment Research’s earnings per share averages are an average based on a survey of analysts that follow Atara Biotherapeutics.

Atara Biotherapeutics (NASDAQ:ATRA) last issued its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($1.02) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.97) by ($0.05).

Several equities analysts have recently issued reports on ATRA shares. Canaccord Genuity reiterated a “buy” rating and set a $47.00 price objective on shares of Atara Biotherapeutics in a research report on Monday, September 11th. ValuEngine upgraded Atara Biotherapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. Zacks Investment Research downgraded Atara Biotherapeutics from a “buy” rating to a “hold” rating in a research report on Monday, August 28th. Jefferies Group LLC restated a “buy” rating and issued a $30.00 target price on shares of Atara Biotherapeutics in a research report on Thursday, August 31st. Finally, BidaskClub downgraded Atara Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, August 22nd. Three equities research analysts have rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company. Atara Biotherapeutics currently has a consensus rating of “Hold” and an average price target of $24.40.

ILLEGAL ACTIVITY NOTICE: This story was published by Daily Political and is the sole property of of Daily Political. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright law. The legal version of this story can be read at https://www.dailypolitical.com/2017/11/23/analysts-expect-atara-biotherapeutics-inc-atra-to-post-1-15-earnings-per-share.html.

Shares of Atara Biotherapeutics (NASDAQ:ATRA) traded down $0.15 during midday trading on Monday, hitting $14.35. The stock had a trading volume of 107,600 shares, compared to its average volume of 232,002. Atara Biotherapeutics has a fifty-two week low of $11.80 and a fifty-two week high of $23.00.

In other Atara Biotherapeutics news, EVP Christopher Haqq sold 6,000 shares of the company’s stock in a transaction on Friday, September 15th. The stock was sold at an average price of $15.30, for a total value of $91,800.00. Following the transaction, the executive vice president now owns 349,305 shares of the company’s stock, valued at $5,344,366.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Gad Soffer sold 7,000 shares of the company’s stock in a transaction on Friday, November 17th. The shares were sold at an average price of $15.00, for a total value of $105,000.00. Following the completion of the transaction, the executive vice president now directly owns 166,342 shares in the company, valued at approximately $2,495,130. The disclosure for this sale can be found here. Insiders sold 45,988 shares of company stock valued at $674,308 over the last 90 days. 16.20% of the stock is currently owned by insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Dimensional Fund Advisors LP increased its holdings in shares of Atara Biotherapeutics by 2.9% in the second quarter. Dimensional Fund Advisors LP now owns 21,718 shares of the biotechnology company’s stock valued at $304,000 after buying an additional 610 shares in the last quarter. American International Group Inc. increased its holdings in shares of Atara Biotherapeutics by 7.1% in the first quarter. American International Group Inc. now owns 14,304 shares of the biotechnology company’s stock valued at $294,000 after buying an additional 948 shares in the last quarter. Teachers Advisors LLC increased its holdings in shares of Atara Biotherapeutics by 2.4% in the second quarter. Teachers Advisors LLC now owns 47,156 shares of the biotechnology company’s stock valued at $660,000 after buying an additional 1,110 shares in the last quarter. The Manufacturers Life Insurance Company increased its holdings in shares of Atara Biotherapeutics by 7.2% in the second quarter. The Manufacturers Life Insurance Company now owns 20,377 shares of the biotechnology company’s stock valued at $285,000 after buying an additional 1,369 shares in the last quarter. Finally, Alps Advisors Inc. increased its holdings in shares of Atara Biotherapeutics by 5.8% in the second quarter. Alps Advisors Inc. now owns 26,274 shares of the biotechnology company’s stock valued at $368,000 after buying an additional 1,445 shares in the last quarter. 82.52% of the stock is currently owned by institutional investors.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.

Get a free copy of the Zacks research report on Atara Biotherapeutics (ATRA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.